The choice between these classes often depends on individual patient factors, comorbidities (particularly heart failure or chronic kidney disease), and tolerability
Eli Lilly and Company, the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), has announced positive topline results from a phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes
Walking after meals to stimulate digestion
Regulation of cell proliferation and apoptosis: Glutathione depletion is a signal for apoptosis (programmed cell death), while adequate levels support normal cell proliferation [2][5]
Gastrointestinal effects: Concomitant use of diclofenac and prednisolone in the treatment of arthritis may provide additional therapeutic benefit and permit reduction of glucocorticoid dosage